Table 1:
Clinical features of patients and postoperative neurological efficacy
| Gender (female/male) | 15/22 |
| Age (years), median (range) | 50.0 (45.0–60.0) |
| Body mass index (kg/m2), median (range) | 23.9 (20.7–25.5) |
| MGFA classification (I/II/III/IV) | 12/22/3/0 |
| Maximal tumour diameter (cm), median (range) | 2.2 (1.8–2.7) |
| Pathological diagnosis (thymoma/non-thymoma) | 18/19 |
| FEV1 (% of predicted), median (range) | 65.0 (62.0–67.0) |
| Preoperative plasmapheresis (cases) | 4 |
| Conversion to thoracotomy/sternotomy, n (%) | 1 (2.7) |
| Operation time (min), median (range) | 80.0 (60.0–100.0) |
| Estimated blood loss (ml), median (range) | 50.0 (50.0–100.0) |
| Myasthenia crisis after surgery, n (%) | 2 (5.4) |
| Chest tube duration (days), median (range) | 3.0 (2.5–4.5) |
| Total drainage volume (ml), median (range) | 170.0 (100.0–250.0) |
| Hospital stay after surgery (days), median (range) | 6.0 (5.0–7.5) |
| Wound infection/delayed healing, n (%) | 1 (2.7) |
| Temporary phrenic nerve paresis, n (%) | 2 (5.4) |
| Obvious residual soft tissue in anterior mediastinum by CT, n (%) | 4 (10.8) |
| Patients followed up, n (%) | 29 (78.4) |
| Follow-up (months), median (range) | 34.0 (23.5–50.0) |
| Neurological outcomes, n (%) | |
| Overall clinical improvement (CSR/PR) | 18 (62.1) |
| CSR | 5 (17.2) |
| Ineffective (unchanged/worse) | 11 (10/1) |
Data are reported as n (%) or median and interquartile range.
CSR: complete stable remission; FEV1: forced expiratory volume in the first second; MGFA: Myasthenia Gravis Foundation of America; PR: pharmacological remission.